CTRI/2022/11/047050进行中（未招募）4 期
A Phase IV study to evaluate the safety and efficacy of Placida® [Fixed Dose Combination of Flupentixol 0.5 mg + Melitracen 10 mg] in comparison to Escitalopram 10 mg + Clonazepam 0.5 mg in patients with comorbid anxiety and depression.
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1) Male or female patients 18-65 years of age.
- •2) Patients suffering from mild to moderate comorbid anxiety and depression according to ICD-10 criteria and prescribed either combination of escitalopram and clonazepam or Placida®.
- •3) No life-threatening, severe, or unstable disease/disorders or major cognitive deficits at baseline.
- •4) Women of childbearing potential must: a) have a negative urine pregnancy test, b) not be nursing, and c) be willing to use acceptable methods of contraception throughout the study period.
- •5) Must provide written informed consent prior to study initiation.
排除标准
- •1) Patients with strong suicidal tendencies.
- •2) Patients with severe mental illnesses that could confuse assessment of depression and anxiety.
- •3) Patients with severe anxiety and depression; with HAM-A score >25 and HAM-D Score >19.
- •4) Patients participating in any clinical trial currently or with in past 3 months.
- •5) Contraindications to the study drugs according to the prescribing information.
- •6) Treatment resistant anxiety/depression.
- •7) Hypersensitivity to study drugs or to any of the excipients.
- •8) Patients with organic brain syndrome, convulsion, urinary retention, hyperthyroidism, advanced hepatic or cardiovascular disease and any other serious uncontrolled concomitant disease that would contraindicate the use of any drug used in this study or that would put the patient at
- •high risk for study treatment-related complications.
- •9) Patients unable to comply with the protocol requirements.
- •10) Patients with continuing history of alcohol and/or drug abuse.
- •11) Patients taking a mono-amine oxidase inhibitor (MAOI), or within 14 days of discontinuing treatment with MAOI.
- •12) Patients on other maintenance medications for
- •anxiety/depression.
研究者
相似试验
进行中（未招募）
4 期
To assess how safe and effective Visanne (Dienogest) is in managing pelvic pain caused due to endometriosisCTRI/2022/04/041870Bayer Pharmaceuticals Pvt Ltd
已完成
4 期
To collect the safety and efficacy data in patients with metastatic colorectalcancer after giving regorafenib in Indianpatients.CTRI/2018/06/014371Bayer AG100
进行中（未招募）
1 期
Study to assess the efficacy and safety of a basal insulin (Glargine 300) on glycemic control type 2 diabetic patients during hospitalization and at discharge.MedDRA version: 18.1Level: LLTClassification code 10049746Term: Insulin-requiring type II diabetes mellitusSystem Organ Class: 100000004861Type 2 DiabetesEUCTR2015-004715-20-ESSANOFI-AVENTIS, S.A.106
招募中
不适用
A Clinical Study to Evaluate Efficacy and Safety of Imatinib (Glinib®) in Pateitns with LeukiemiaDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0002068Dong-A ST150
已完成
4 期
A Post Marketing study of VELSEAL to control the bleeding from severely bleeding wounds due to accidents, trauma cases and deep arterial wounds.CTRI/2018/03/012373Datt Mediproducts Pvt Ltd101